Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 27.12% | -36.46% | 317.43% | -68.67% | -12.64% |
| Total Depreciation and Amortization | 5.15% | 4.40% | -4.22% | 8.93% | 2.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.63% | 123.30% | 68.42% | -15.95% | 14.24% |
| Change in Net Operating Assets | -87.38% | 127.20% | -290.09% | 50.65% | 215.30% |
| Cash from Operations | -12.52% | 1,388.36% | -90.29% | -21.40% | 97.69% |
| Capital Expenditure | 4.93% | -3.08% | 33.37% | -69.39% | -16.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | 103.99% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.98% | -1,873.61% | 105.02% | 61.27% | -201.55% |
| Cash from Investing | -32.71% | -108.19% | 53.20% | 53.65% | -148.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -32.16% | -21.92% | 113.31% | -6.92% | -39.34% |
| Repurchase of Common Stock | -160.60% | 89.79% | -1,185.22% | 92.46% | -9,694.55% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 300.00% | -147.06% | 154.84% | 98.69% | -23,710.00% |
| Cash from Financing | -33,500.00% | 99.93% | -3,857.89% | 98.46% | -1,504.36% |
| Foreign Exchange rate Adjustments | -373.68% | -53.66% | 134.29% | 450.00% | 96.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.14% | 193.94% | -301.06% | 141.11% | -521.53% |